CSIMarket
 
Pyxis Oncology Inc   (PYXS)
Other Ticker:  
 
 
Price: $5.1200 $0.38 8.017%
Day's High: $5.23 Week Perf: -11.88 %
Day's Low: $ 4.69 30 Day Perf: 0.99 %
Volume (M): 752 52 Wk High: $ 6.92
Volume (M$): $ 3,851 52 Wk Avg: $2.79
Open: $4.75 52 Wk Low: $1.35



 Market Capitalization (Millions $) 212
 Shares Outstanding (Millions) 41
 Employees 11
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -94
 Cash Flow (TTM) (Millions $) -184
 Capital Exp. (TTM) (Millions $) 9

Pyxis Oncology Inc
Pyxis Oncology Inc is a clinical-stage biopharmaceutical company which is focused on developing innovative cancer therapies. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology has a unique approach to cancer therapy, using a proprietary platform to identify and validate novel therapeutic targets. The platform is designed to identify targets that are important for tumor growth and survival, but are not currently targeted by existing therapies. This enables Pyxis to develop drugs that have the potential to be more effective and better tolerated than existing cancer treatments.

At the core of Pyxis Oncology's platform is a cutting-edge technology called Mass Spec. Mass Spec is a powerful tool that allows the company to identify thousands of proteins in tumor cells and compare them to normal cells. This enables Pyxis to identify proteins that are unique to cancer cells and target them with therapies that have a high specificity and low toxicity.

Pyxis Oncology's lead drug candidate is PYX-202, which is a monoclonal antibody targeting a protein called OX40. OX40 is a key regulator of T-cell function and has been shown to be important for tumor growth and survival. PYX-202 is currently in Phase I clinical trials for the treatment of advanced solid tumors.

In addition to PYX-202, Pyxis Oncology has a pipeline of other drug candidates targeting novel therapeutic targets. These include drugs targeting proteins such as CD73, CD39, and PSMA.

Pyxis Oncology has a world-class team of scientists and clinicians who have extensive experience in oncology drug development. The company has also built strong partnerships with leading academic institutions and pharmaceutical companies to accelerate the development of its drug candidates.

Overall, Pyxis Oncology is a promising biopharmaceutical company that is working to develop innovative cancer therapies that have the potential to make a significant impact on the lives of cancer patients.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 221-9059   Stock Exchange / Ticker: NASDAQ PYXS
   PYXS is expected to report next financial results on March 21, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Pyxis Oncology Announces $50 Million Private Placement, Fueling Growth Potential for Share Value

Published Tue, Feb 27 2024 1:00 PM UTC

Pyxis Oncology Announces $50 Million Private Placement, Potential Impact on Share Value
Boston-based Pyxis Oncology, a clinical stage company specializing in innovative therapeutics for difficult-to-treat cancers, has recently disclosed its agreement to a private placement of its common stock and pre-funded warrants. The company has agreed to sell 8,849,371 shares of its...

Pyxis Oncology Inc

Pyxis Oncology Inc Breaks the Mould: Positive Growth Amidst Operating Shortfall

Despite facing an operating shortfall, Pyxis Oncology Inc (PYXS) is showing promising signs of growth in the Major Pharmaceutical Preparations industry. The company's recent earnings report reveals a narrowing operating shortfall of $-25.354 million for the third quarter of 2023, compared to $-28.393 million in the same period of the previous year. These positive numbers indicate that PYXS is moving in the right direction and making strides towards achieving its business objectives.
For small companies like PYXS, efficient operations are crucial for long-term success. As they continue to develop their business strategy, it is vital for them to demonstrate consistent improvement and cut down on diminishing returns. In the July to September 2023 period, PYXS managed to decrease the operating shortfall to $-23.049 million from $-27.674 million in the previous year's third quarter. This demonstrates the company's determination and ability to make strategic adjustments to enhance its financial performance.

Pyxis Oncology Inc

Major Pharmaceutical Preparations Leader, Pyxis Oncology Inc, Demonstrates Remarkable Operating Deficit Improvement in Q2 2023 Earnings Season



As the April to June 2023 reporting season continues, Wall Street analysts are closely scrutinizing the financial results of various companies, including those in the Major Pharmaceutical Preparations industry. One such entity, PYXS, recently published their operating deficit for the second quarter of the 2023 earnings season. The company's performance showed a significant reduction in operating deficit compared to the same period last year. This positive development has sparked optimism among market observers and warrants a closer examination.
Operating Deficit Improvement:
PYXS reported an operating deficit of $-18.121 million for the second quarter of 2023, which represents a substantial improvement compared to the operating deficit of $-25.726 million in the corresponding period a year ago. This performance suggests that the company is moving towards a more favorable financial position.

Pyxis Oncology Inc

Pyxis Oncology Inc Shows Improvement in Operating Shortfall, Reducing it from $-31.389 Million in 2022 to $-20.954 Million in First Quarter of 2023

The Major Pharmaceutical Preparations industry is closely monitoring the first quarter results for 2023, with a particular focus on Pyxis Oncology Inc. The company has reported an operating shortfall of $-20.954 million, however, it has yet to state any revenue during the January to March 31, 2023 reporting season.
Despite this, industry experts have noted that the company is showing signs of more efficient operations when compared to the corresponding period a year ago, with a decrease in operating shortfall from $-31.389 million in 2022 to $-20.954 million in 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com